Vancomycin-resistant enterococci infection: not just for the transplanted

References

• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091–2101.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751.
   PubMed Web of Science ®Google Scholar
• Schimpff SC, Gaya H, Klastersky J, et al. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group.J Infect Dis 1978;137:14–29.
   PubMedGoogle Scholar
• Freifeld AG, Baden LR, Brown AE, et al. Fever and neutropenia clinical practice guidelines. J Natl Compr Canc Netw 2004;2:390–432.
   PubMedGoogle Scholar
• Avery R, Kalaycio M, Pohlman B, et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 2005;35:497–499.
   PubMed Web of Science ®Google Scholar
• Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004;39(Suppl. 1):S25–S31.
   PubMed Web of Science ®Google Scholar
• Craig M, Cumpston AD, Hobbs GR, et al. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant 2007;39:477–482.
   PubMed Web of Science ®Google Scholar
• Cumpston A, Craig M, Hamadani M, et al. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit. Transpl Infect Dis 2013;15:142–149.
   PubMed Web of Science ®Google Scholar
• Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?. J Antimicrob Chemother 2013;68:731–742.
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163–170.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• Paul M, Borok S, Fraser A, et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005;55:436–444.
   PubMed Web of Science ®Google Scholar
• Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2007;13:615–621.
   PubMed Web of Science ®Google Scholar
• Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008;29:996–1011.
   PubMed Web of Science ®Google Scholar
• Rice LB. Antimicrobial pressure and the emergence and spread of multiresistant enterococci. Postgrad Med 2001;109:22–31.
   PubMedGoogle Scholar
• McDonald LC, Kuehnert MJ, Tenover FC, et al. Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerg Infect Dis 1997;3: 311–317.
   PubMed Web of Science ®Google Scholar
• Cheah AL, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect 2013;19:E181–E189.
   Web of Science ®Google Scholar
• Vydra J, Shanley RM, George I, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012;55: 764–770.
   PubMed Web of Science ®Google Scholar
• Calderwood MS, Mauer A, Tolentino J, et al. Epidemiology of vancomycin-resistant enterococci among patients on an adult stem cell transplant unit: observations from an active surveillance program. Infect Control Hosp Epidemiol 2008;29:1019–1025.
   PubMed Web of Science ®Google Scholar
• Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 2010;19:231–237.
   PubMed Web of Science ®Google Scholar
• Peel T, Cheng AC, Spelman T, et al. Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia. Clin Microbiol Infect 2012;18:388–394.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.
   PubMed Web of Science ®Google Scholar
• Rolston KV, Jiang Y, Matar M. VRE fecal colonization/infection in cancer patients. Bone Marrow Transplant 2007;39:567–568.
   PubMed Web of Science ®Google Scholar
• Zaas AK, Song X, Tucker P, et al. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002;35:1139–1146.
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Hollands JM, Georgantopoulos P, et al. Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker?Bone Marrow Transplant 2006;38:813–819.
   PubMed Web of Science ®Google Scholar
• Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 2010;16:1576–1581.
   PubMed Web of Science ®Google Scholar
• Knoll M, Daeschlein G, Okpara-Hofmann J, et al. Outbreak of vancomycin-resistant enterococci (VRE) in a hematological oncology ward and hygienic preventive measures. A long-term study. Onkologie 2005;28:187–192.
   PubMed Web of Science ®Google Scholar
• Worth LJ, Thursky KA, Seymour JF, et al. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007;79:226–233.
   PubMed Web of Science ®Google Scholar
• Zirakzadeh A, Gastineau DA, Mandrekar JN, et al. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008;41: 385–392.
   PubMed Web of Science ®Google Scholar
• McKinnell JA, Kunz DF, Chamot E, et al. Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol 2012;33:718–724.
   PubMed Web of Science ®Google Scholar
• Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008;52:2403–2406.
   PubMed Web of Science ®Google Scholar
• Weber SG, Huang SS, Oriola S, et al. Society for Healthcare Epidemiology of America; Association of Professionals in Infection Control and Epidemiology. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol 2007;28:249–260.
   PubMed Web of Science ®Google Scholar
• Tschudin Sutter S, Frei R, Dangel M, et al. Not all patients with vancomycin-resistant enterococci need to be isolated. Clin Infect Dis 2010;51:678–683.
   PubMed Web of Science ®Google Scholar
• Salgado CD, Ison MG. Should clinicians worry about vancomycin-resistant Enterococcus bloodstream infections?. Bone Marrow Transplant 2006;38:771–774.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Zimmer SM, Klein M, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327–333.
   PubMed Web of Science ®Google Scholar